Status:

COMPLETED

An Evaluation of the Effects of a Non-Caffeinated Energy Dietary Supplement

Lead Sponsor:

Nova Southeastern University

Conditions:

Health Behavior

Eligibility:

All Genders

18-50 years

Phase:

NA

Brief Summary

This study tested the effects of a botanical blend to a caffeine and a placebo condition on 1) self-reported alertness, anxiety, and headaches 2) multiple measures of attention 3) physical performance...

Detailed Description

This study aimed to build on this work by investigating the possibility that a specific botanical blend (Phytovive™); comprised of Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, po...

Eligibility Criteria

Inclusion

  • Adult males and females from 18 to 50 years (inclusive) of age who are physically active and have been engaging in athletic and sporting endeavors consistently over a period of 6 months at minimum
  • BMI 18.0 (normal) to 34.9 (obese, class I) kg/ m2 inclusive
  • Agrees to maintain a stable lifestyle with no change in exercise or diet for the duration of the study
  • Current consumer of caffeine either through caffeinated beverages or foods
  • Non-smoker
  • Able to physically exercise, to run on a treadmill at moderate to high intensity for a brief time (typically less than 20 min)
  • Participants with normal blood pressure or participants with hypertension that is controlled (BP \< 160/90 and who are on medication at a stable dose (same dose for ≥90 days)
  • Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, carry out all study-related procedures, communicate effectively with the study staff.
  • Females must be using an acceptable method of contraception such as: abstinence, double barrier (condom, diaphragm, or cervical cap with spermicidal foam, gel, or cream), intrauterine device or hormonal contraception (oral, injectable, implantable, transdermal, or vaginal) used consecutively for at least 3 months prior to screening visit, vasectomized partner or use of implants for at least 6 months prior to screening visit; bilateral tubal ligation, hysterectomy, bilateral oophorectomy, or be postmenopausal status with amenorrhea (no menses) for at least 1 year prior to the screening visit.

Exclusion

  • Have a known sensitivity or allergy to any of the study products or their ingredients
  • Have any medical condition or disease based on the professional judgement and experience of the principal investigator (PI) plus research industry standards that might affect or impact the administration of study products
  • Lactating, pregnant or planning to become pregnant during the study
  • History of drug or alcohol abuse in the 12 months prior to screening
  • History of psychiatric illness requiring hospitalization in the 6 months prior to screening
  • History of diabetes (Type I or II) or uncontrolled hypertension (either systolic BP \>160 or diastolic BP \>90)
  • Participation in or use of a research IP within 30 days prior to screening (cannot have been in another study within 30 days of screening)

Key Trial Info

Start Date :

January 3 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 15 2021

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT04895800

Start Date

January 3 2020

End Date

March 15 2021

Last Update

June 9 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Nova Southeastern University

Davie, Florida, United States, 33314